Shopping Cart
- Remove All
- Your shopping cart is currently empty
Sphingolactone-24 (50 µM; 30 min+24 h) inhibits p38 MAPK phosphorylation induced by LPS and counters its anti-apoptotic effects.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | Sphingolactone-24 (50 µM; 30 min+24 h) inhibits p38 MAPK phosphorylation induced by LPS and counters its anti-apoptotic effects. |
In vitro | Sphingolactone-24 (50 µM; 30 min+24 h) inhibits p38 MAPK phosphorylation induced by LPS and counters its anti-apoptotic effects. |
In vivo | Sphingolactone-24, administered at a dose of 1 mg/kg intraperitoneally at 3 and 9 hours post LPS exposure, mitigates the severity of LPS-induced acute lung injury (ALI) and enhances survival rates in mice subjected to pulmonary damage due to LPS. In this study, the animal model utilized was C3H/HeN breeder mice, which received LPS at 10 mg/kg via intranasal instillation. The treatment not only improved survival but also significantly reduced the severity of ALI. |
Alias | Sph-24 |
Molecular Weight | 323.43 |
Formula | C18H29NO4 |
Cas No. | 881177-99-7 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.